BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Shooting of MIT professor Nuno Loureiro has police searching for a suspect- NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- Share your pick for the riding area that characterizes your surf undertakings!
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- FDA approves Wegovy pill for weight loss
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
